The REMINDER study evaluated the effect of MRAs initiated in the first 24 h in STEMI patients without a history of HF, with a composite primary endpoint of cardiovascular mortality, re-hospitalization or extended initial hospital stay, due to diagnosis of heart failure, sustained ventricular arrhythmias, EF < 40%, or elevated BNP/NT-proBNP at 1 month or more after randomization. The gene discussed is NPPB; the disease is heart failure.